Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1229-1234

  Van Rijn, Sander P ^a   Van Altena, Richard ^a   Akkerman, Onno W ^a   Van Soolingen, Dick ^b,c   Van Der Laan, Tridia ^c   De Lange, Wiel C M ^a   Kosterink, Jos G W ^a   Van Der Werf, Tjip S ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CAPREOMYCIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; ERTAPENEM; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; BETA LACTAM; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CROHN DISEASE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SPUTUM SMEAR; TREATMENT DURATION; UNIVERSITY; VOLUME OF DISTRIBUTION; VOMITING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BETA-LACTAMS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84964067831     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01654-2015     Document Type: Article

References (33)

1. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
2. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
3. Watt B, Edwards JR, Rayner A, et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber Lung Dis 1992; 73: 134-136.
4. Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-2821.
5. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
6. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016; 47: 333-336.
7. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; 46: 1461-1470.
8. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry 2007; 46: 11998-12004.
9. Cordillot M, Dubée V, Triboulet S, et al. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob Agents Chemother 2013; 57: 5940-5945.
10. Veziris N, Truffot C, Mainardi JL, et al. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 2011; 55: 2597-2600.
11. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47: Suppl. 1, S32-S40.
12. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-1052.
13. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53: Suppl. 2, ii75-ii81.
14. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53: Suppl. 2, ii23-ii28.
15. Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-1358.
16. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668.
17. van Rijn SP, Wessels AM, Greijdanus B, et al. Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother 2014; 58: 3481-3484.
18. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-3511.
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
20. van de Kassteele J, van Santen-Verheuvel MG, Koedijk FD, et al. New statistical technique for analyzing MIC-based susceptibility data. Antimicrob Agents Chemother 2012; 56: 1557-1563.
21. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014; 91: 47-55.
22. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur Respir J 2012; 40: 990-1013.
23. Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009; 33: 432-436.
24. Burkhardt O, Derendorf H, Welte T. Ertapenem: The new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007; 8: 237-256.
25. Sauermann R, Burian B, Burian A, et al. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. J Antimicrob Chemother 2013; 68: 895-899.
26. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
27. Dong H, Wang X, Dong Y, et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011; 38: 296-300.
28. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
29. Hess S, Hospach T, Nossal R, et al. Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. Eur J Pediatr 2011; 170: 1337-1342.
30. Zhanel GG, Simor AE, Vercaigne L, et al. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 1998; 9: 215-228.
31. Srivastava S, van Rijn SP, Sherman C, et al. Sterilizing activity of ertapenem (ETP) against Mycobacterium tuberculosis (Mtb). Poster presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, USA, September 17-21, 2015.
32. Esteban J, Ortiz A, Jiménez MS. Usefulness of E-test strips for testing susceptibility of Mycobacterium tuberculosis complex strains. Eur J Clin Microbiol Infect Dis 2005; 24: 856-857.
33. Caminero JA, Scardigli A. Classification of antituberculosis drugs: A new proposal based on the most recent evidence. Eur Respir J 2015; 46: 887-893.